AbbVie shares weekly forecast: Overbought CCI reading highlights correction risk as momentum holds

Traders Union
All News
Stocks
Abbvie advances 0.88% this week

Highlights

AbbVie stock trades at $293.89, holding above key short-term trend levels with strong upward momentum.
Technical readings show a bullish trend, though overbought conditions introduce the potential for a short-term pullback.
The expected trading range is $284.62 to $304.62, with $288.04 as key support and $302.68 as resistance.

Earnings strength and pipeline deals reinforce sentiment as outlook improves

AbbVie reported strong third quarter 2026 results, including net revenue of approximately $17.4 billion and a raised full-year earnings outlook along with a 5.2% dividend increase, according to Yahoo Finance. The company’s strengths in immunology and neuroscience were reinforced by robust sales of key products. Additional news included positive Phase 4 trial data in Allergan Aesthetics and the announcement of a global licensing deal with Nxera Pharma to expand the immunology pipeline.

Bullish momentum persists this week even as oscillators warn of correction

The daily chart shows a sustained move higher with a firm trend, underscored by a bullish MACD reading of 6.48 and a constructive ADX. CCI's overbought status at 110.18 points to some possible correction risk, but overall oscillator signals are mostly neutral. The nearest support sits at the 20-day moving average of $288.04, with resistance at the recent weekly high of $302.68. Volatility has registered at 7.35%, indicative of an active trading environment.

Bullish bias prevails next week as breakout and support levels guide range

In the week ahead, AbbVie shares are expected to trade in the $284.62 to $304.62 range, with a very high probability of an increase and a very low probability of a decrease. The base case is for continued strength within this range, anchored by strong momentum. A break above $302.68 could open the way for further gains, given current trend signals. However, a drop below $288.04 would place focus on the Ichimoku Kijun support at $281.78 as the next key downside level.

Sholanke Dele, market strategist, sees AbbVie stock hovering near $294 as momentum from recent gains shows signs of exhaustion. He notes strong Q3 results, upbeat guidance, and a higher dividend have fueled sentiment, but technicals highlight a stretched daily setup—overbought CCI at 110.18 and growing volatility at 7.35% increase the risk of a near-term pullback. Dele remains cautious for the week ahead, with the 20-day moving average at $288.04 acting as key support; a break below this could shift focus to $281.78, while only a move past $302.68 suggests renewed upside. His base case is continued range-bound strength, but not without reservation given the overextended momentum. "Positive headlines support the rally, but overbought signals mean I’m defensive until there’s a confirmed breakout above $302.68 or a healthy retest of support."

Earlier, analysts noted that AbbVie’s technical setup suggested a constructive trend with the potential for further gains, though a possible near-term inflection point was highlighted. Current price action and indicator readings confirm continued strength, but with overbought signals emerging, traders should closely watch the $302.68 resistance for signs of either an extended breakout or the start of a corrective pullback.

Source of Data: ABBV Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.